株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌免疫療法の世界市場 - 分析・予測 (2018-2028年):モノクロナール抗体・チェックポイント阻害剤・癌ワクチン

Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-2028

発行 BIS Research Inc. 商品コード 785683
出版日 ページ情報 英文 191 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.91円で換算しております。
Back to Top
癌免疫療法の世界市場 - 分析・予測 (2018-2028年):モノクロナール抗体・チェックポイント阻害剤・癌ワクチン Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-2028
出版日: 2019年02月08日 ページ情報: 英文 191 Pages
概要

世界の癌免疫療法市場は、2028年までに1,707億米ドルへ達すると予測されています。

当レポートでは、世界の癌免疫療法市場を調査し、市場の概要、市場成長の促進要因・課題・機会、各セグメント別の市場規模、地域市場の分析、および主要企業のプロファイルなどを提供しています。

エグゼクティブサマリー

第1章 市場概要

  • イントロダクション
  • 癌免疫療法
  • 癌免疫療法の種類

第2章 市場力学

  • 市場成長推進因子
  • 市場成長抑制因子
  • 市場機会

第3章 競合考察

  • 主な戦略発展
    • 製品認可
    • 合意、コラボレーション & 提携
    • 臨床研究
    • 買収
    • その他
  • 市場シェア分析

第4章 産業考察

  • 規制機関/団体/コンソーシアム
  • 特許情勢
  • 規制の指定

第5章 世界の癌免疫療法市場:製品別

  • モノクロナール抗体
  • チェックポイント阻害剤
  • 癌ワクチン

第6章 世界の癌免疫療法市場:適応症別

  • 乳癌
  • 非小細胞肺癌 (NSCLC)
  • メラノーマ
  • 大腸癌
  • 腎細胞癌
  • 消化器癌
  • その他

第7章 世界の癌免疫療法市場:地域別

  • 北米
  • 欧州
  • アジア太平洋 (APAC)
  • ラテンアメリカ
  • その他 (ROW)

第8章 企業プロファイル

  • 概要
  • Aduro Biotech
  • Amgen
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Celgene Corporation
  • DNAtrix Therapeutics
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Fate Therapeutics
  • F. Hoffmann La Roche
  • JOHNSON & JOHNSON
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Precision BioSciences, Inc.
  • IOVANCE BIOTHERAPEUTICS, INC

第9章 調査範囲・調査手法

図表

List of Tables

  • Table 1: Total Regional Geriatric Population (%), 2015 and 2030
  • Table 2: Impact analysis of Market Drivers
  • Table 3: Impact Analysis of Market Restraints
  • Table 1.1: Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society
  • Table 2.1: R&D Expense of Major Companies
  • Table 3.1: Key Company Acquisitions, 2015-2018
  • Table 4.1: Regulatory Organizations/ Associations.
  • Table 4.2: Important Regulatory Designations
  • Table 5.1: List of Monoclonal Antibodies Used in Immunotherapy
  • Table 5.2: PD-L1 Inhibitors and Their FDA Approved Indication
  • Table 5.3: PD-1 Inhibitors and Their FDA Approved Indication
  • Table 6.1: Estimated Incidence, Mortality and Prevalence of Breast Cancer in 2012 (Numbers in thousands)
  • Table 6.2: Top 25 countries with the highest rates of breast cancer in 2018:
  • Table 6.3: Estimated Incidence, Mortality, and Prevalence of Lung Cancer (for both sexes) in 2012 (Numbers in thousands)
  • Table 6.4: NSCLC: 5-Year Survival Rate by Stage
  • Table 6.5: Age Standardized rate of Colorectal cancer in 2018
  • Table 6.6: Estimated Incidence, Mortality, and Prevalence of Different Cancer (for both sexes) Worldwide in 2012
  • Table 6.7: Cervical Cancer Rates: Top 20 Countries in 2018
  • Table 6.8: Leukaemia: Top 10 Countries with Incidence Rates
  • Table 7.1: The U.S. Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.2: Canada Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.3: Germany Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.4: The U.K. Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.5: China Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.6: Japan Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.7: India Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.8: Australia Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.9: Brazil Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.10: Mexico Estimated Age-Standardized Incidence Rates in 2018
  • Table 7.11: Argentina Estimated Age-Standardized Incidence Rates in 2018
  • Table 8.1: Aduro Biotech: Pipeline Products
  • Table 8.2: Celgene Product Pipeline
  • Table 8.3: DNAtrix Therapeutics: Pipeline Products
  • Table 8.4: Fate Therapeutics: Pipeline Products

List of Figures

  • Figure 1: Global Cancer Immunotherapy Market, 2017 and 2028
  • Figure 2: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
  • Figure 3: Global Cancer Immunotherapy Market (by Product), 2017 and 2028
  • Figure 4: Global Cancer Immunotherapy Market (by Therapeutic Indication), 2017 and 2028
  • Figure 5: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
  • Figure 1.1: Treatment for Cancer
  • Figure 1.2: Global Cancer Immunotherapy Market, 2017-2028 ($Billion)
  • Figure 1.3: Key Players Involved in Cancer Immunotherapy
  • Figure 2.1: Market Dynamics
  • Figure 3.1: Share of Key Developmental Strategies, 2015-2018
  • Figure 3.2: Product Approvals, (by Company), 2015-2018
  • Figure 3.3: Agreements, Collaborations and Partnerships, (by Company), 2015-2018
  • Figure 3.4: Clinical Study, (by Company), 2015-2018
  • Figure 3.5: Regulatory Designations, (by Company), 2015-2018
  • Figure 3.6: Other Strategies (by Company), 2015-2018
  • Figure 3.7: Market Share Analysis, 2017 and 2018
  • Figure 4.1: Share of Patents by Ownership, 2015-2018
  • Figure 5.1: Global Monoclonal Antibodies Market, 2017-2028
  • Figure 5.2: Global Checkpoint Inhibitors Market, 2017-2028
  • Figure 5.3: Global Cancer Vaccine Market, 2017-2028
  • Figure 5.4: Development of CAR-T Therapy
  • Figure 5.5: Global Cancer Immunotherapy Market for Other Products, 2017-2028
  • Figure 6.1: Types of Therapeutic Cancer Indications
  • Figure 6.2: Global Breast Cancer Immunotherapy Market, 2017-2028
  • Figure 6.3: Global NSCLC Immunotherapy Market, 2017-2028
  • Figure 6.4: Global Melanoma Immunotherapy Market, 2017-2028
  • Figure 6.5: Global Colorectal Cancer Immunotherapy Market, 2017-2028
  • Figure 6.6: Global Renal Cell Carcinoma Immunotherapy Market, 2017-2028
  • Figure 6.7: Global Gastric Cancer Immunotherapy Market, 2017-2028
  • Figure 6.8: Global Cancer Immunotherapy Market for Other Cancer Indications, 2017-2028
  • Figure 7.1: Global Cancer Immunotherapy (by Region)
  • Figure 7.2: Global Cancer Immunotherapy Market (by Region), 2017-2028
  • Figure 7.3: North America Cancer Immunotherapy Market
  • Figure 7.4: North America Cancer Immunotherapy Market, by Country
  • Figure 7.5: The U.S. Cancer Immunotherapy Market, 2017-2028
  • Figure 7.6: Canada Cancer Immunotherapy Market
  • Figure 7.7: Europe Cancer Immunotherapy Market
  • Figure 7.8: Germany Cancer Immunotherapy Market, 2017-2028
  • Figure 7.9: The U.K. Cancer Immunotherapy Market, 2017-2028
  • Figure 7.10: France Cancer Immunotherapy Market, 2017-2028
  • Figure 7.11: Spain Cancer Immunotherapy Market, 2017-2028
  • Figure 7.12: Italy Cancer Immunotherapy Market, 2018-2028
  • Figure 7.13: Russia Cancer Immunotherapy Market, 2018-2028
  • Figure 7.14: Poland Cancer Immunotherapy Market, 2018-2028
  • Figure 7.15: Austria Cancer Immunotherapy Market, 2018-2028
  • Figure 7.16: Switzerland Cancer Immunotherapy Market, 2018-2028
  • Figure 7.17: Belgium Cancer Immunotherapy Market, 2018-2028
  • Figure 7.18: The Netherlands Cancer Immunotherapy Market, 2018-2028
  • Figure 7.19: Sweden Cancer Immunotherapy Market, 2018-2028
  • Figure 7.20: Finland Cancer Immunotherapy Market, 2018-2028
  • Figure 7.21: Denmark Cancer Immunotherapy Market, 2018-2028
  • Figure 7.22: Ireland Cancer Immunotherapy Market, 2018-2028
  • Figure 7.23: Rest-of-Europe Cancer Immunotherapy Market, 2018-2028
  • Figure 7.24: Asia-Pacific Cancer Immunotherapy Market, 2017-2028
  • Figure 7.25: China Cancer Immunotherapy Market, 2017-2028
  • Figure 7.26: Japan Cancer Immunotherapy Market, 2017-2028
  • Figure 7.27: India Cancer Immunotherapy Market, 2017-2028
  • Figure 7.28: Australia Cancer Immunotherapy Market, 2017-2028
  • Figure 7.29: S. Korea Cancer Immunotherapy Market, 2017-2028
  • Figure 7.30: New Zealand Cancer Immunotherapy Market, 2017-2028
  • Figure 7.31: Malaysia Cancer Immunotherapy Market, 2017-2028
  • Figure 7.32: Bangladesh Cancer Immunotherapy Market, 2017-2028
  • Figure 7.33: Rest-of-Asia-Pacific Cancer Immunotherapy Market, 2017-2028
  • Figure 7.34: Latin America Cancer Immunotherapy Market, 2017-2028
  • Figure 7.35: Latin America Cancer Immunotherapy Market (by Country), 2017-2028
  • Figure 7.36: Brazil Cancer Immunotherapy Market, 2017-2028
  • Figure 7.37: Mexico Cancer Immunotherapy Market, 2017-2028
  • Figure 7.38: Argentina Cancer Immunotherapy Market, 2017-2028
  • Figure 7.39: Rest-of-Latin-America Cancer Immunotherapy Market, 2017-2028
  • Figure 7.40: Saudi Arabia Cancer Immunotherapy Market, 2017-2028
  • Figure 7.41: The U.A.E. Cancer Immunotherapy Market, 2017-2028
  • Figure 7.42: South Africa Cancer Immunotherapy Market, 2017-2028
  • Figure 7.43: Israel Cancer Immunotherapy Market, 2017-2028
  • Figure 7.44: Others Cancer Immunotherapy Market, 2017-2028
  • Figure 8.1: Aduro Biotech: Overall Financials, 2015-2017
  • Figure 8.2: Aduro Biotech: Research and Development Expense, 2015-2017
  • Figure 8.3: Aduro Biotech: SWOT Analysis
  • Figure 8.4: Amgen Inc: Cancer Immunotherapy Product Portfolio
  • Figure 8.5: Amgen Inc.: Overall Financials
  • Figure 8.6: Amgen Inc.: Net Revenue (by Region), 2015-2017
  • Figure 8.7: Amgen Inc.: R&D Expenditure, 2015-2017
  • Figure 8.8: Amgen Inc.: SWOT Analysis
  • Figure 8.9: AstraZeneca PLC: Cancer Immunotherapy Product Portfolio
  • Figure 8.10: AstraZeneca PLC: Overall Financials, 2015-2017
  • Figure 8.11: AstraZeneca PLC: Net Revenue (by Business Segment), 2015-2017
  • Figure 8.12: AstraZeneca PLC: Revenue: Net Revenue (by Regions), 2015-2017
  • Figure 8.13: AstraZeneca PLC: R&D Expenditure, 2015-2017
  • Figure 8.14: AstraZeneca PLC: SWOT Analysis
  • Figure 8.15: Bristol-Myers Squibb: Product Portfolio
  • Figure 8.16: Bristol-Myers Squibb: Overall Financials
  • Figure 8.17: Bristol-Myers Squibb: Net Revenue (by Regions), 2015-2017
  • Figure 8.18: Bristol-Myers Squibb: R&D Expenditure, 2015-2017
  • Figure 8.19: Bristol-Myers Squibb: SWOT Analysis
  • Figure 8.20: Celgene Corporation: Overall Financials
  • Figure 8.21: Celgene Corporation: Net Revenue (by Region), 2015-2017
  • Figure 8.22: Celgene Corporation: R&D Expenditure, 2015-2017
  • Figure 8.23: Celgene Corporation: SWOT Analysis
  • Figure 8.24: DNAtrix Therapeutics: SWOT Analysis
  • Figure 8.25: Eli Lilly and Company: Product Portfolio
  • Figure 8.26: Eli Lilly and Company: Overall Financials, 2015-2017
  • Figure 8.27: Eli Lilly and Company: Net Revenue (by Business Segments), 2015-2017
  • Figure 8.28: Eli Lilly and Company: Net Revenue (by Regions), 2015-2017
  • Figure 8.29: Eli Lilly and Company: Research and Development Expenditure, 2015-2017
  • Figure 8.30: Eli Lilly and Company: SWOT Analysis
  • Figure 8.31: Gilead Sciences, Inc.: Overall Financials
  • Figure 8.32: Gilead Sciences, Inc.: Net Revenue (by Region), 2015-2017
  • Figure 8.33: Gilead Sciences, Inc.: Research and Development Expenditure, 2015-2017
  • Figure 8.34: Gilead Sciences, Inc.: SWOT Analysis
  • Figure 8.35: Fate Therapeutics: Overall Financials
  • Figure 8.36: Fate Therapeutics: Research and Development Expenditure, 2015-2017
  • Figure 8.37: Fate Therapeutics: SWOT Analysis
  • Figure 8.38: F. Hoffmann La Roche AG: Product Portfolio
  • Figure 8.39: F. Hoffmann La Roche: Overall Financials
  • Figure 8.40: F. Hoffmann La Roche: Net Revenue (by Business Segment), 2015-2017
  • Figure 8.41: F. Hoffmann La Roche: Net Revenue (by Geographic Regions), 2015-2017
  • Figure 8.42: F. Hoffmann La Roche: Research and Development Expense, 2015-2017
  • Figure 8.43: F. Hoffmann La Roche: SWOT Analysis
  • Figure 8.44: JOHNSON & JOHNSON: Overall Financials, 2015-2017
  • Figure 8.45: JOHNSON & JOHNSON (by Business Segment), 2015-2017
  • Figure 8.46: JOHNSON & JOHNSON (by Region), 2015-2017
  • Figure 8.47: JOHNSON & JOHNSON: Research and Development Expense, 2015-2017
  • Figure 8.48 JOHNSON & JOHNSON: SWOT ANALYSIS
  • Figure 8.49: Merck & Co, Inc.: Product Portfolio
  • Figure 8.50: Merck & Co, Inc.: Overall Financials
  • Figure 8.51: Merck & Co, Inc. (by Business Segment), 2015-2017
  • Figure 8.52: Merck & Co, Inc (by Geographic Regions), 2015-2017
  • Figure 8.53: Merck & Co, Inc.: Research and Development Expense, 2015-2017
  • Figure 8.54: Merck & Co, Inc.: SWOT Analysis
  • Figure 8.55: Novartis AG: Cancer Immunotherapy Product Portfolio
  • Figure 8.56: Novartis AG: Overall Financials (2015-2017)
  • Figure 8.57: Novartis AG (by Business Segment), 2015-2017
  • Figure 8.58 Novartis AG (by Geographic Region), 2015-2017
  • Figure 8.59 Novartis AG: Research and Development Expenditure, 2015-2017
  • Figure 8.60: Novartis AG: SWOT Analysis
  • Figure 8.61: Pfizer, Inc.: Cancer Immunotherapy Product Portfolio
  • Figure 8.62: Pfizer, Inc.: Overall Financials, 2015-2017
  • Figure 8.63: Pfizer, Inc.: Net Revenue (by Business Segment), 2015-2017
  • Figure 8.64: Pfizer, Inc.: Net Revenue (by Region), 2015-2017
  • Figure 8.65: Pfizer, Inc.: Research and Development Expense, 2015-2017
  • Figure 8.66: Pfizer, Inc.: SWOT Analysis
  • Figure 8.67: Precision BioSciences, Inc.: SWOT Analysis
  • Figure 9.1: Global Cancer Immunotherapy Market Segmentation
  • Figure 9.2: Research Methodology
  • Figure 9.3: Primary Research Sources
  • Figure 9.4: Secondary Research Sources
  • Figure 9.5: Key Data Points from Primary and Secondary Sources
  • Figure 9.6: Data Triangulation
  • Figure 9.7: Top-Down Approach: Global Cancer Immunotherapy Market
  • Figure 9.8: Bottom-up Approach: Global Cancer Immunotherapy Market
  • Figure 9.9: Assumptions and Limitations
目次
Product Code: BH096A

"Global Cancer Immunotherapy Market to Reach $170.70 billion by 2028."

The healthcare industry is a multi-billion-dollar market consisting of various verticals aimed at improving patient lives. The industry has experienced considerable advancement in terms of diagnosis and treatment, yet cancer remains as one of the leading causes of death. Cancer acts as one of the major issues of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO). The effects of cancer have had a major impact on society across the world and currently accounts for almost 70% of death in low- and middle-income countries. As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives. As a result, significant scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of cancer treatment market. Cancer immunotherapy or, immuno-oncology, is the treatment that utilises the body's own immune system to combat cancer. These immunotherapy treatments either boost the body's immune system or may act on immune system to identify and destroy the cancerous cells. Immunotherapy is a type of personalized medicine that works better for certain types of cancer. Globally, patients are displaying a positive response towards advanced cancer therapy drugs which effectively help manage and treat their medical conditions. This, in turn, is gradually increasing the adoption rate of the cancer immunotherapy drugs.

The cancer immunotherapy market consists of products such as monoclonal antibodies, check point inhibitors, cancer vaccines and other medicinal treatments such as adoptive cell therapies and oncolytic viral therapies used in the treatment of cancer. The market analysis report includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, gastric cancer, and others. Geographically, the market can be segmented into five distinct regions including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.

The purpose of the study is to gain a holistic view of the global cancer immunotherapy market in terms of various factors influencing the same, such as key market trends, competitive and regulatory aspects of the market, scientific innovations in the oncology field, etc. The scope of the report is centred upon conducting a detailed study of the solutions allied with cancer immunotherapy market, which involves drugs used in different therapeutic applications of cancer treatment. The global cancer immunotherapy market is segmented into three different parts: 'by products', 'by therapeutic indication', and 'by region'. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.

The answers to the following key questions can be derived from this report:

  • What is cancer immunotherapy? What are the products included in immunotherapy?
  • What are the major market drivers, restraints, and opportunities in the global cancer immunotherapy market?
  • What were the market shares of the leading segments, and sub-segments of the global cancer immunotherapy market in 2017 and what will be its share in 2028?
  • How will each segment of the global cancer immunotherapy market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
  • What are the influencing factors that may affect the market share of the key players?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What are the major regulatory authorities/ associations/ consortiums affecting the cancer immunotherapy market and what are the main designations facilitating development and approval of cancer drugs?
  • Which product segment is expected to register the highest CAGR for the global cancer immunotherapy market?
  • How has the market been segmented based on therapeutic indication? Which therapeutic indication segment had the largest share, and the fastest growth rate in the global cancer immunotherapy market?
  • Which geographical region will contribute to the highest sales of the cancer immunotherapy drugs during the forecast period and which will have the highest CAGR?
  • What are major companies developing cancer immunotherapy drugs targeted for different therapeutic indication?

The key players that have been contributing significantly in the cancer immunotherapy market include: Aduro Biotech, Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Gilead Sciences, Inc., among others.

Executive Summary

The healthcare industry has made incredible advancement in diagnosis and treatment of all kinds of diseases that could not be cured earlier, yet cancer remains as one of the leading causes of death. As per the World Health Organisation (WHO) -- Cancer was responsible for an estimated 9.6 million deaths in 2018. The rising geriatric population is likely to increase the incidence and prevalence of cancer in the coming years. As per data from Surveillance, Epidemiology, and End Results (SEER) program of the U.S.-based government health agency National Cancer Institute (NCI), approximately 83-84% of the known cancer cases occur in people aged 50 years and above globally. The geriatric population is at an increased risk as cancer occurs due to genetic aberrations or mutations in the human DNA. In simpler terms, with age, our cells get damaged due to an unhealthy lifestyle like smoking or exposure to ultra-violet rays, and accumulation of these damaged cells (which recover fast at a younger age as compared to when we are old) over a lifetime is one of the prominent causes of cancer. According to WHO, cancer claimed 8.8 million lives in 2015 and accounted for almost 1 in 6 global deaths. In low- and middle- income countries, about 70% of deaths are caused due to cancer, resulting in a significant burden on the healthcare and economy of these countries. The treatment of cancer is long-term and involves extensive therapies that are expensive, and act as an economic burden on the patients and their families. It has been estimated that global spending on cancer therapies and supportive care drugs exceed $133 billion and is expected to increase to $200 billion by 2022.

Cancer Immunotherapy or, immuno-oncology, is the treatment that utilizes the body's self-immune system to combat cancer. The immunotherapy treatments either boost the body's immune system against cancer or acts as the immune system to identify the cancerous cells and destroy them. Immunotherapy is precision (personalized) medicine that works better for some types of cancer; however, this treatment is now used for different types of cancer. The first immunotherapy treatment, Yervoy, was approved and commercialized in 2011 by US-based bio-pharmaceutical company, Bristol-Myers Squibb.

Recently with the discovery of new oncology targets and increased knowledge about cancer, newer immunotherapy options have been discovered. For e.g., approval of novel checkpoints (targets in the body of a patient with cancer) inhibitors against PD-1 and PD-L1, have revolutionized the immune-oncology market with their rapid uptake among the patients. The global cancer immunotherapy market was valued at $39.86 billion in 2017 and is anticipated to reach $170.70 billion by 2028. The rising prevalence of cancer around the world and high unmet medical needs of patients with cancer are stimulators for the growth of the cancer immunotherapy market. In addition, the advancements in precision medicine for immuno-oncology and rise in expenditure by pharmaceutical companies on R&D for cancer treatments, are contributing to the rise in demand for cancer immunotherapy as a treatment for cancer.

The purpose of the BIS Research study, Global Cancer Immunotherapy Market, is to gain a holistic view of the global cancer immunotherapy market against various factors influencing the market, such as the key market trends, competitive and regulatory aspects of the market, scientific innovations into oncology fields, etc. The scope of the report is centered upon a detailed study of the solutions allied with cancer immunotherapy market which involves immune-oncology drugs used in different therapeutic applications for cancer treatment. The global cancer immunotherapy market is segmented into three different parts: 'by products', 'by therapeutic indication', and 'by region'. The global market value for cancer immunotherapy was estimated using these three different approaches and was validated against one another. These segments are further segmented into several sub-segments to ease the market estimation.

Based on products, the market can be sub-segmented into monoclonal antibodies, check point inhibitors, cancer vaccine, and others. The market for monoclonal antibodies dominates the market in terms of revenue. The growth of the monoclonal antibodies market is accredited to the efficacy of these targeted antibodies, rising demand for advanced oncology medicines along with an increase in the research and development facilities globally. However, Check Point Inhibitors exhibit a higher growth rate as they have shown to be more efficacious and have less toxicity as compared to other product classes. These products have a novel mechanism of action which have revolutionized the cancer immunotherapy market.

Based on therapeutic indication, the market can be classified into seven major cancer types, which include breast cancer, melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma, gastric cancer, and others. Among the different types of cancers, breast cancer is the leading contributor to metastatic cancer treatment market, while the highest CAGR is expected to be registered by NSCLC during the forecast period from 2018 to 2028.

Geographically, the market is sub-segmented into five distinct regions -- North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World. North America leads the market in terms of revenue, followed by Europe. Within North America, the U.S. generated almost 96% of the total revenue share, and the rest 4 % of the revenue was generated by Canada in 2017. Within Europe, Germany dominated the market in 2017 with a revenue share of 16.73%. However, the market for Asia-pacific region is expected to demonstrate the highest growth rate, during the forecast period from 2018 to 2028, as compared to other regions.

The cancer immunotherapy market has a promising potential for growth in the coming years. The report provides an in-depth SWOT analysis of different key players of the market, supported by an extensive financial summary of each company. The key players of the market are Aduro Biotech, Inc, Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim, Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Gilead Sciences, Inc, among others.

Table of Contents

Executive Summary

1. Market Overview

  • 1.1. Cancer Immunotherapy
  • 1.2. Types of Cancer Immunotherapy

2. Market Dynamics

  • 2.1. Drivers
    • 2.1.1. Rising Prevalence of Cancer
    • 2.1.2. Unmet Medical Needs of Cancer Patients
    • 2.1.3. Rising R&D Expenditure in the Immuno-Oncology Segment
    • 2.1.4. Advancement of Precision Medicine in Immuno-oncology
  • 2.2. Restraints
    • 2.2.1. High Cost of Treatment
    • 2.2.2. Adverse Effects of Immunotherapy Treatment
  • 2.3. Opportunities
    • 2.3.1. Development of Targeted Therapy
    • 2.3.2. Development of Healthcare Infrastructure and Reimbursement Policies in Emerging Economies
    • 2.3.3. Combination Therapy

3. Competitive Landscape

  • 3.1. Key Developmental Strategies
    • 3.1.1. Product Approval
    • 3.1.2. Agreements, Collaborations and Partnerships
    • 3.1.3. Clinical Study
    • 3.1.4. Regulatory Designation
    • 3.1.5. Acquisition
    • 3.1.6. Others
  • 3.2. Market Share Analysis

4. Industry Insights

  • 4.1. Regulatory Organizations/ Associations/ Consortiums
  • 4.2. Patent Landscape
  • 4.3. Regulatory Designations

5. Global Cancer Immunotherapy Market (By Product)

  • 5.1. Monoclonal Antibodies
  • 5.2. Checkpoint Inhibitors
    • 5.2.1. CTLA-4 Inhibitors
    • 5.2.2. PD-L1 Inhibitors/ PD-1 Inhibitors
  • 5.3. Cancer Vaccines
    • 5.3.1. Other Cancer Therapies
      • 5.3.1.1. Oncolytic Viruses
      • 5.3.1.2. Adoptive Cell Transfer

6. Global Cancer Immunotherapy Market (by Therapeutic Indication)

  • 6.1. Breast Cancer
  • 6.2. Non-Small Cell Lung Cancer (NSCLC)
  • 6.3. Melanoma
  • 6.4. Colorectal Cancer
  • 6.5. Renal Cell Carcinoma
  • 6.6. Gastric Cancer
  • 6.7. Others

7. Global Cancer Immunotherapy Market (by Region)

  • 7.1. North America
    • 7.1.1. The U.S.
    • 7.1.2. Canada
  • 7.2. Europe
    • 7.2.1. Germany
    • 7.2.2. The U.K.
    • 7.2.3. France
    • 7.2.4. Spain
    • 7.2.5. Italy
    • 7.2.6. Russia
    • 7.2.7. Poland
    • 7.2.8. Austria
    • 7.2.9. Switzerland
    • 7.2.10 Belgium
    • 7.2.11 The Netherlands
    • 7.2.12 Sweden
    • 7.2.13 Finland
    • 7.2.14 Denmark
    • 7.2.15. Ireland
    • 7.2.16. Rest-of-Europe
  • 7.3. Asia-Pacific
    • 7.3.1. China
    • 7.3.2. Japan
    • 7.3.3. India
    • 7.3.4. Australia
    • 7.3.5. South Korea
    • 7.3.6. New Zealand
    • 7.3.7. Malaysia
    • 7.3.8. Bangladesh
    • 7.3.9. Rest-of-Asia-Pacific
  • 7.4. Latin America
    • 7.4.1. Brazil
    • 7.4.2. Mexico
    • 7.4.3. Argentina
    • 7.4.4. Rest-of-Latin-America
  • 7.5. Rest-of-the-World (RoW)
    • 7.5.1. Saudi Arabia
    • 7.5.2. The U.A.E.
    • 7.5.3. South Africa
    • 7.5.4. Israel
    • 7.5.5. Others

8. Company Profiles

  • 8.1. Overview
  • 8.2. Aduro Biotech
    • 8.2.1. Company Overview
    • 8.2.2. Role of Aduro Biotech in Cancer Immunotherapy Market
    • 8.2.3. Financials
    • 8.2.4. Key Insights about the Financial Health of the Company
    • 8.2.5. SWOT Analysis
  • 8.3. Amgen
    • 8.3.1. Company Overview
    • 8.3.2. Role of Amgen Inc in the Cancer Immunotherapy Market
    • 8.3.3. Financials
    • 8.3.4. Key Insights about Financial Health of the Company
    • 8.3.5. SWOT Analysis
  • 8.4. AstraZeneca PLC
    • 8.4.1. Company Overview
    • 8.4.2. Role of AstraZeneca in Cancer Immunotherapy Market
    • 8.4.3. Financials
    • 8.4.4. Key Insights about Financial Health of the Company
    • 8.4.5. SWOT Analysis
  • 8.5. Bristol-Myers Squibb
    • 8.5.1. Company Overview
    • 8.5.2. Role of Bristol-Myers Squibb in the Cancer Immunotherapy Market
    • 8.5.3. Financials
    • 8.5.4. Key Insights about Financial Health of the Company
    • 8.5.5. SWOT Analysis
  • 8.6. Celgene Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Role of Celgene Corporation in Cancer Immunotherapy Market
    • 8.6.3. Financials
    • 8.6.4. Key Insights about Financial Health of the Company
    • 8.6.5. SWOT Analysis
  • 8.7. DNAtrix Therapeutics
    • 8.7.1. Company Overview
    • 8.7.2. Role of DNAtrix Therapeutics in Cancer Immunotherapy Market
    • 8.7.3. SWOT Analysis
  • 8.8. Eli Lilly and Company
    • 8.8.1. Company Overview
    • 8.8.2. Role of Eli Lilly and Company in Cancer Immunotherapy Market
    • 8.8.3. Financials
    • 8.8.4. Key Insights about Financial Health of the Company
    • 8.8.5. SWOT Analysis
  • 8.9. Gilead Sciences, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Role of Gilead Sciences, Inc. in Cancer Immunotherapy Market
    • 8.9.3. Financials
    • 8.9.4. Key Insights About the Financial Health of the Company
    • 8.9.5. SWOT Analysis
  • 8.10 Fate Therapeutics
    • 8.10.1. Company Overview
    • 8.10.2. Role of Fate Therapeutics in cancer immunotherapy market
    • 8.10.3. Financials
    • 8.10.4. Key Insights about the Financial Health of the Company
    • 8.10.5. SWOT Analysis
  • 8.11 F. Hoffmann La Roche
    • 8.11.1. Company Overview
    • 8.11.2. Role of F. Hoffmann La Roche in Cancer Immunotherapy market
    • 8.11.3. Financials
    • 8.11.4. Key Insights About the Financial Health of the Company
    • 8.11.5. SWOT Analysis
  • 8.12 JOHNSON & JOHNSON
    • 8.12.1. Company Overview
    • 8.12.2. Role of Johnson & Johnson in Cancer Immunotherapy Market
    • 8.12.3. Financials
    • 8.12.4. Key Insights about the Financial Health of the Company
    • 8.12.5. SWOT Analysis
  • 8.13 Merck & Co., Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Role of Merck & Co, Inc. in Cancer Immunotherapy Market
    • 8.13.3. Financials
    • 8.13.4. Key Insights about the Financial Health of Company
    • 8.13.5. SWOT Analysis
  • 8.14 Novartis AG
    • 8.14.1. Company Overview
    • 8.14.2. Role of Novartis AG in Cancer Immunotherapy Market
    • 8.14.3. Financials
    • 8.14.4. Key Insights about the Financial Health of Company
    • 8.14.5. SWOT Analysis
  • 8.15 Pfizer, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Role of Pfizer, Inc. in Cancer Immunotherapy Market
    • 8.15.3. Financials
    • 8.15.4. Key Insights about the Financial Health of the Company
    • 8.15.5. SWOT Analysis
  • 8.16 Precision BioSciences, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Role of Precision BioSciences, Inc. in Cancer Immunotherapy Market
    • 8.16.3. SWOT Analysis
  • 8.17 IOVANCE BIOTHERAPEUTICS, INC.: Snapshot
    • 8.17.1. Company Overview
    • 8.17.2. Role of IOVANCE BIOTHERAPEUTICS, INC. in cancer immunotherapy market

9. Research Scope and Methodology

  • 9.1. Scope of the Report
  • 9.2. Global Cancer Immunotherapy Market Segmentation
  • 9.3. Research Methodology
    • 9.3.1. Primary Research
    • 9.3.2. Secondary Research
    • 9.3.3. Key Data Points from Primary and Secondary Sources
    • 9.3.4. Data Triangulation
    • 9.3.5. Top-Down Approach
    • 9.3.6. Bottom- Up Approach
  • 9.4. Assumptions and Limitations
Back to Top